- Home
- BCLI vs PPBT Comparison
BCLI vs PPBT Comparison
Compare BCLI & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- PPBT
- Stock Information
- Founded
- BCLI 2000
- PPBT 2010
- Country
- BCLI United States
- PPBT Israel
- Employees
- BCLI N/A
- PPBT N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- PPBT Health Care
- Exchange
- BCLI Nasdaq
- PPBT Nasdaq
- Market Cap
- BCLI 7.9M
- PPBT 6.5M
- IPO Year
- BCLI N/A
- PPBT N/A
- Fundamental
- Price
- BCLI $1.16
- PPBT $2.20
- Analyst Decision
- BCLI Strong Buy
- PPBT Strong Buy
- Analyst Count
- BCLI 1
- PPBT 1
- Target Price
- BCLI $30.00
- PPBT $33.00
- AVG Volume (30 Days)
- BCLI 141.4K
- PPBT 285.3K
- Earning Date
- BCLI 05-15-2025
- PPBT 05-23-2025
- Dividend Yield
- BCLI N/A
- PPBT N/A
- EPS Growth
- BCLI N/A
- PPBT N/A
- EPS
- BCLI N/A
- PPBT N/A
- Revenue
- BCLI N/A
- PPBT N/A
- Revenue This Year
- BCLI N/A
- PPBT N/A
- Revenue Next Year
- BCLI N/A
- PPBT N/A
- P/E Ratio
- BCLI N/A
- PPBT N/A
- Revenue Growth
- BCLI N/A
- PPBT N/A
- 52 Week Low
- BCLI $0.72
- PPBT $2.00
- 52 Week High
- BCLI $10.05
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- BCLI 50.13
- PPBT 35.17
- Support Level
- BCLI $1.12
- PPBT $2.16
- Resistance Level
- BCLI $1.26
- PPBT $2.41
- Average True Range (ATR)
- BCLI 0.14
- PPBT 0.21
- MACD
- BCLI 0.02
- PPBT -0.01
- Stochastic Oscillator
- BCLI 42.86
- PPBT 16.48
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.